Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)
Massachusetts General Hospital
100 participants
Nov 24, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
Eligibility
Inclusion Criteria4
- Age ≥ 18 years old at time of signing informed consent
- Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment
- a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment
- Able to provide informed consent
Exclusion Criteria5
- Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
- BMI <25 kg/m2 at the time of screening
- Unable to participate in a regular physical exercise program
- Implanted pacemaker
- Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be provided a smartwatch to monitor their exercise and body composition
Participants will receive general guidance on recommended exercise
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07226947